
In the phase 3 OASIS-4 trial (NCT05587296), elinzanetant (Lynkuet) produced clinically meaningful reductions in moderate-to-severe vasomotor symptoms frequency—beginning as early as week 1—compared with placebo, with improvements extending across all menopause-related quality-of-life domains.














